Probiotics decreased the bioavailability of the bile acid analog, monoketocholic acid, when coadministered with gliclazide, in healthy but not diabetic rats.

European journal of drug metabolism and pharmacokinetics 20120601

Physicochemical investigations and stability studies of amorphous gliclazide.

AAPS PharmSciTech 20120601

Gliclazide may have an antiapoptotic effect related to its antioxidant properties in human normal and cancer cells.

Molecular biology reports 20120501

Novel tamarind seed polysaccharide-alginate mucoadhesive microspheres for oral gliclazide delivery: in vitro-in vivo evaluation.

Drug delivery 20120401

KCNJ11 gene E23K variant and therapeutic response to sulfonylureas.

European journal of internal medicine 20120401

Protective effects of combined therapy of gliclazide with curcumin in experimental diabetic neuropathy in rats.

Behavioural pharmacology 20120401

Pharmacogenomic analysis of ATP-sensitive potassium channels coexpressing the common type 2 diabetes risk variants E23K and S1369A.

Pharmacogenetics and genomics 20120301

Variations in tissue selectivity amongst insulin secretagogues: a systematic review.

Diabetes, obesity & metabolism 20120201

Glycaemic control and cost analysis when changing from gliclazide co-administered with metformin to pre-combined glibenclamide-metformin tablets in type 2 diabetes mellitus.

The Medical journal of Malaysia 20120201

Effects of pioglitazone add-on to gliclazide and metformin on glycemic control in patients with type 2 diabetes.

Endocrine research 20120101

Treating diabetes today with gliclazide MR: a matter of numbers.

Diabetes, obesity & metabolism 20120101

Protective effects of beta glucan and gliclazide on brain tissue and sciatic nerve of diabetic rats induced by streptozosin.

Experimental diabetes research 20120101

Gliclazide does not fully prevent 2-deoxy-D-ribose-induced oxidative damage because it does not restore glutathione content in a pancreatic β-cell line.

Oxidative medicine and cellular longevity 20120101

Antidiabetic effect of S-allylcysteine: effect on thyroid hormone and circulatory antioxidant system in experimental diabetic rats.

Journal of diabetes and its complications 20120101

[Diabetes mellitus and chronic kideny disease: modern diagnostics and treatment].

Vestnik Rossiiskoi akademii meditsinskikh nauk 20120101

Does glycemic control offer similar benefits among patients with diabetes in different regions of the world? Results from the ADVANCE trial.

Diabetes care 20111201

Development, optimization, and anti-diabetic activity of gliclazide-loaded alginate-methyl cellulose mucoadhesive microcapsules.

AAPS PharmSciTech 20111201

[Incretin-based therapy for treating patients with type 2 diabetes].

Orvosi hetilap 20111127

High-performance affinity chromatography and the analysis of drug interactions with modified proteins: binding of gliclazide with glycated human serum albumin.

Analytical and bioanalytical chemistry 20111101

[Hypoglycemia].

Praxis 20111019

Effect of binary and ternary solid dispersions on the in vitro dissolution and in-situ rabbit intestinal absorption of gliclazide.

Pakistan journal of pharmaceutical sciences 20111001

Dissolution rate enhancement of gliclazide by ordered mixing.

Acta pharmaceutica (Zagreb, Croatia) 20110901

Antidiabetic and antioxidant potentials of Euphorbia hirta leaves extract studied in streptozotocin-induced experimental diabetes in rats.

General physiology and biophysics 20110901

AMP-activated protein kinase is activated in adipose tissue of individuals with type 2 diabetes treated with metformin: a randomised glycaemia-controlled crossover study.

Diabetologia 20110701

Intensive glucose control and risk of cancer in patients with type 2 diabetes.

Diabetologia 20110701

Comparison of the dipeptidyl peptidase-4 inhibitor vildagliptin and the sulphonylurea gliclazide in combination with metformin, in Muslim patients with type 2 diabetes mellitus fasting during Ramadan: results of the VECTOR study.

Current medical research and opinion 20110701

Formulation and evaluation of Ficus glomerata mucilage sustained release matrix tablets of gliclazide.

Pakistan journal of pharmaceutical sciences 20110701

Pharmacokinetic-pharmacodynamic equivalence of three gliclazide formulations in healthy human male subjects.

International journal of clinical pharmacology and therapeutics 20110701

Reduced catalytic activity of human CYP2C9 natural alleles for gliclazide: molecular dynamics simulation and docking studies.

Biochimie 20110601

Effects of gliclazide on endothelial function in patients with newly diagnosed type 2 diabetes.

European journal of pharmacology 20110601

Diagnosis in diabetes: does it matter?

The journal of the Royal College of Physicians of Edinburgh 20110601

Molecular dynamics simulation of drug uptake by polymer.

Journal of molecular modeling 20110501

In vitro-in vivo correlation for gliclazide immediate-release tablets based on mechanistic absorption simulation.

AAPS PharmSciTech 20110301

Insulin and metformin may prevent renal injury in young type 2 diabetic Goto-Kakizaki rats.

European journal of pharmacology 20110225

Comparison of two sulfonylureas with high and low myocardial K(ATP) channel affinity on myocardial infarct size and metabolism in a rat model of type 2 diabetes.

Diabetologia 20110201

Design and development of gliclazide-loaded chitosan microparticles for oral sustained drug delivery: in-vitro/in-vivo evaluation.

The Journal of pharmacy and pharmacology 20110201

Design and development of gliclazide-loaded chitosan for oral sustained drug delivery: in vitro/in vivo evaluation.

Journal of microencapsulation 20110101

Response to oral gliclazide in a pre-pubertal child with hepatic nuclear factor-1 alpha maturity onset diabetes of the young.

Annals of Saudi medicine 20110101

Effect of repaglinide and gliclazide on glycaemic control, early-phase insulin secretion and lipid profiles in.

Chinese medical journal 20110101

Ramsay Hunt syndrome with unilateral polyneuropathy involving cranial nerves V, VII, VIII, and XII in a diabetic patient.

Quintessence international (Berlin, Germany : 1985) 20110101

[Comparative characteristics of antioxidant properties of hypoglycemic agents diabenol and gliclazide].

Eksperimental'naia i klinicheskaia farmakologiia 20110101

Design and evaluation of a novel formulation prediction system.

International journal of pharmaceutics 20101215

Antidiabetic effect of S-allylcysteine: Effect on plasma and tissue glycoproteins in experimental diabetes.

Phytomedicine : international journal of phytotherapy and phytopharmacology 20101201

Beneficial effect of S-allylcysteine (SAC) on blood glucose and pancreatic antioxidant system in streptozotocin diabetic rats.

Plant foods for human nutrition (Dordrecht, Netherlands) 20101201

Hydrochloride pioglitazone decreases urinary cytokines excretion in type 2 diabetes.

Clinical endocrinology 20101201

Use of sulphonylurea and cancer in type 2 diabetes-The Hong Kong Diabetes Registry.

Diabetes research and clinical practice 20101201

Erectile dysfunction and later cardiovascular disease in men with type 2 diabetes: prospective cohort study based on the ADVANCE (Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified-Release Controlled Evaluation) trial.

Journal of the American College of Cardiology 20101130

Severe hypoglycemia and risks of vascular events and death.

The New England journal of medicine 20101007

Effects of metformin plus gliclazide compared with metformin alone on circulating endothelial progenitor cell in type 2 diabetic patients.

Endocrine 20101001

Effects of gliclazide on platelet aggregation and the plasminogen activator inhibitor type 1 level in patients with type 2 diabetes mellitus.

Metabolism: clinical and experimental 20100901

Physicochemical characterization of gliclazide-macrogol solid dispersion and tablets based on optimized dispersion.

Drug development and industrial pharmacy 20100801

The efficacy of lowering glycated haemoglobin with a gliclazide modified release-based intensive glucose lowering regimen in the ADVANCE trial.

Diabetes research and clinical practice 20100801

Resveratrol attenuates hyperglycemia-mediated oxidative stress, proinflammatory cytokines and protects hepatocytes ultrastructure in streptozotocin-nicotinamide-induced experimental diabetic rats.

Chemico-biological interactions 20100730

Preparation and in vitro evaluation of gliclazide sustained-release matrix pellets: formulation and storage stability.

Drug development and industrial pharmacy 20100701

Maintenance of glycaemic control with the evening administration of a long acting sulphonylurea in male type 2 diabetic patients undertaking the Ramadan fast.

International journal of clinical practice 20100701

Gliclazide microcrystals prepared by two methods of in situ micronization: pharmacokinetic studies in diabetic and normal rats.

AAPS PharmSciTech 20100601

Effect of gliclazide on nucleotide excision repair (NER) and non-homologous DNA end joining (NHEJ) in normal and cancer cells.

Journal of physiology and pharmacology : an official journal of the Polish Physiological Society 20100601

Influence of CYP2C9 and CYP2C19 genetic polymorphisms on pharmacokinetics and pharmacodynamics of gliclazide in healthy Chinese Han volunteers.

Journal of clinical pharmacy and therapeutics 20100601

Three novel mutations in MODY and its phenotype in three different Czech families.

Diabetes research and clinical practice 20100501

Effects of short-term therapy with different insulin secretagogues on glucose metabolism, lipid parameters and oxidative stress in newly diagnosed Type 2 Diabetes Mellitus.

Diabetes research and clinical practice 20100401

Comparison of ultraviolet detection, evaporative light scattering detection and charged aerosol detection methods for liquid-chromatographic determination of anti-diabetic drugs.

Journal of pharmaceutical and biomedical analysis 20100311

Comparison of insulin sensitivity, glucose sensitivity, and first phase insulin secretion in patients treated with repaglinide or gliclazide.

Archives of pharmacal research 20100301

Comparison of metformin, gliclazide MR and rosiglitazone in monotherapy and in combination for type 2 diabetes.

Arquivos brasileiros de endocrinologia e metabologia 20100301

A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with Type 2 diabetes inadequately controlled with metformin alone: a 52-week, randomized study.

Diabetic medicine : a journal of the British Diabetic Association 20100301

Evaluation of different tests based on observations for external model evaluation of population analyses.

Journal of pharmacokinetics and pharmacodynamics 20100201

Evaluation of efficacy and tolerability of gliclazide and metformin combination: a multicentric study in patients with type 2 diabetes mellitus uncontrolled on monotherapy with sulfonylurea or metformin.

American journal of therapeutics 20100101

Present status of sulfonylurea treatment for type 2 diabetes in Japan: second report of a cross-sectional survey of 15,652 patients.

Endocrine journal 20100101

[Dynamics of structural-functional parameters of cardiovascular system during use of complex therapy of women with type 2 diabetes mellitus].

Kardiologiia 20100101

[Capabilities of hypoglycemic therapy in women with decompensated type 2 diabetes mellitus].

Terapevticheskii arkhiv 20100101

Sulphonylureas and cancer: a case-control study.

Acta diabetologica 20091201

Efficacy and safety comparison between the DPP-4 inhibitor vildagliptin and the sulfonylurea gliclazide after two years of monotherapy in drug-naïve patients with type 2 diabetes.

Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme 20091201

Glibenclamide-related excess in total and cardiovascular mortality risks: data from large Ukrainian observational cohort study.

Diabetes research and clinical practice 20091201

Pharmacokinetics and bioequivalence evaluation of gliclazide/metformin combination tablet and equivalent doses of gliclazide and metformin in healthy Korean subjects.

International journal of clinical pharmacology and therapeutics 20091201

Recent cardiovascular trials: what are the drivers of benefit and adverse effect?

Journal of diabetes 20091201

Suppression of KATP channel activity protects murine pancreatic beta cells against oxidative stress.

The Journal of clinical investigation 20091102

Combined effects of routine blood pressure lowering and intensive glucose control on macrovascular and microvascular outcomes in patients with type 2 diabetes: New results from the ADVANCE trial.

Diabetes care 20091101

Cognitive function and risks of cardiovascular disease and hypoglycaemia in patients with type 2 diabetes: the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial.

Diabetologia 20091101

Is there evidence that oral hypoglycemic agents reduce cardiovascular morbidity or mortality? No.

Diabetes care 20091101

Severe neuroglycopaenia secondary to severe hypoglycaemia from serendipitous overdose of gliclazide without adrenergic or autonomic response.

Diabetic medicine : a journal of the British Diabetic Association 20091101

Effect of gliclazide immobilization into layered double hydroxide on drug release.

European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V 20091001

Vildagliptin therapy and hypoglycaemia in Muslim type 2 diabetes patients during Ramadan.

International journal of clinical practice 20091001

Trace analysis of glyclazide in human plasma at microscale level by mass spectrometry.

Journal of separation science 20091001

Second-generation sulfonylureas preserve inhibition of mitochondrial permeability transition by the mitochondrial K+(ATP) opener nicorandil in experimental myocardial infarction.

Shock (Augusta, Ga.) 20090901

Effects of exposure of human islet beta-cells to normal and high glucose levels with or without gliclazide or glibenclamide.

Diabetes & metabolism 20090901

D-pinitol attenuates the impaired activities of hepatic key enzymes in carbohydrate metabolism of streptozotocin-induced diabetic rats.

General physiology and biophysics 20090901

Pioglitazone-induced acute rhabdomyolysis.

Diabetes care 20090701

The behavior of Gliclazide in solution and in the solid state: a case of organic compound presenting a solid-solution structure.

Magnetic resonance in chemistry : MRC 20090601

Physicochemical properties of solid dispersions of gliclazide in polyvinylpyrrolidone K90.

AAPS PharmSciTech 20090601

Modulatory effects of resveratrol on attenuating the key enzymes activities of carbohydrate metabolism in streptozotocin-nicotinamide-induced diabetic rats.

Chemico-biological interactions 20090515

The oral anti-diabetic agent, gliclazide, inhibits oxidized LDL-mediated LOX-1 expression, metalloproteinase-9 secretion and apoptosis in human aortic endothelial cells.

Atherosclerosis 20090501

Blood pressure and glucose control in subjects with diabetes: new analyses from ADVANCE.

Journal of hypertension. Supplement : official journal of the International Society of Hypertension 20090501

In vive effects of gliclazide and metformin on the plasma concentration of caffeine in healthy rats.

Pakistan journal of biological sciences : PJBS 20090501

Overcome side identification in PPOP by making orifices on both layers.

International journal of pharmaceutics 20090417

Free fatty acid kinetics during long-term treatment with pioglitazone added to sulfonylurea or metformin in Type 2 diabetes.

Journal of internal medicine 20090401

Applying the Taguchi design for optimized formulation of sustained release gliclazide chitosan beads: an in vitro/in vivo study.

AAPS PharmSciTech 20090301

Antidiabetic effects of dipeptidyl peptidase-IV inhibitors and sulfonylureas in streptozotocin-nicotinamide-induced mildly diabetic mice.

Metabolism: clinical and experimental 20090301

Preparation and characterization of gliclazide-polyethylene glycol 4000 solid dispersions.

Acta pharmaceutica (Zagreb, Croatia) 20090301

The metabolism of CYP2C9 and CYP2C19 for gliclazide by homology modeling and docking study.

European journal of medicinal chemistry 20090201

Unexplained severe hypoglycaemia in hospital: a difficult diagnostic challenge.

British journal of clinical pharmacology 20090201

Treatment of HNF1-alpha MODY with the DPP-4 inhibitor Sitagliptin(1).

Diabetic medicine : a journal of the British Diabetic Association 20090201

Antioxidant and vascular effects of gliclazide in type 2 diabetic rats fed high-fat diet.

Physiological research 20090101

Normal insulin response to short-term intense exercise is abolished in Type 2 diabetic patients treated with gliclazide.

Journal of diabetes and its complications 20090101

Normal pregnancy and healthy child after continued exposure to gliclazide and ramipril during pregnancy.

The Annals of pharmacotherapy 20090101

Gliclazide reduces MKC intestinal transport in healthy but not diabetic rats.

European journal of drug metabolism and pharmacokinetics 20090101

Dissolution enhancement of gliclazide using pH change approach in presence of twelve stabilizers with various physico-chemical properties.

Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques 20090101

The efficacy of self-monitoring of blood glucose in the management of patients with type 2 diabetes treated with a gliclazide modified release-based regimen. A multicentre, randomized, parallel-group, 6-month evaluation (DINAMIC 1 study).

Diabetes, obesity & metabolism 20081201

Hyperglycaemia secondary to mirtazapine therapy in a 37-year-old man.

The Australian and New Zealand journal of psychiatry 20081101

Ser1369Ala variant in sulfonylurea receptor gene ABCC8 is associated with antidiabetic efficacy of gliclazide in Chinese type 2 diabetic patients.

Diabetes care 20081001

Comparison of gliclazide with insulin as initial treatment modality in newly diagnosed type 2 diabetes.

Diabetes technology & therapeutics 20081001

optimization of extended zero-order release gliclazide tablets using D-optimal mixture design.

Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan 20081001

Reversible binding of antidiabetic drugs, repaglinide and gliclazide, with human serum albumin.

Chemical biology & drug design 20081001

Daily blood glucose profiles of glibenclamide and gliclazide taken once or twice daily in elderly type 2 diabetic patients.

Geriatrics & gerontology international 20080901

Differential effect of sulfonylureas on production of reactive oxygen species and apoptosis in cultured pancreatic beta-cell line, MIN6.

Metabolism: clinical and experimental 20080801

Is Ramadan fasting safe in type 2 diabetic patients in view of the lack of significant effect of fasting on clinical and biochemical parameters, blood pressure, and glycemic control?

Clinical and experimental hypertension (New York, N.Y. : 1993) 20080701

In vitro effect of gliclazide on DNA damage and repair in patients with type 2 diabetes mellitus (T2DM).

Chemico-biological interactions 20080617

Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.

The New England journal of medicine 20080612

Enhancement of dissolution rate of gliclazide using solid dispersions with polyethylene glycol 6000.

AAPS PharmSciTech 20080601

Rosiglitazone produces a greater reduction in circulating platelet activity compared with gliclazide in patients with type 2 diabetes mellitus--an effect probably mediated by direct platelet PPARgamma activation.

Atherosclerosis 20080401

Effects of St John's wort and CYP2C9 genotype on the pharmacokinetics and pharmacodynamics of gliclazide.

British journal of pharmacology 20080401

Erythromelalgia in a diabetic patient managed with gabapentin.

Diabetes research and clinical practice 20080301

Therapeutic options for elderly diabetic subjects: open label, randomized clinical trial of insulin glargine added to oral antidiabetic drugs versus increased dosage of oral antidiabetic drugs.

Acta diabetologica 20080301

Spermicidal activity of sulfonylureas and meglitinide analogues: role of intrasperm Ca2+ elevation.

The Journal of pharmacy and pharmacology 20080301

Design and development of gliclazide mucoadhesive microcapsules: in vitro and in vivo evaluation.

AAPS PharmSciTech 20080301

[Effects of Tangweian granule on 5-HT(2A)R in rat model with diabetic gastroparesis].

Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica 20080301

Influence of the semisynthetic bile acid MKC on the ileal permeation of gliclazide in vitro in healthy and diabetic rats treated with probiotics.

Methods and findings in experimental and clinical pharmacology 20080301

Antiglycation effect of gliclazide on in vitro AGE formation from glucose and methylglyoxal.

Experimental biology and medicine (Maywood, N.J.) 20080201

Hypoglycemic effects of a sesquiterpene glycoside isolated from leaves of loquat (Eriobotrya japonica (Thunb.) Lindl.).

Phytomedicine : international journal of phytotherapy and phytopharmacology 20080101

Decreased in vivo oxidative stress and decreased platelet activation following metformin treatment in newly diagnosed type 2 diabetic subjects.

Diabetes/metabolism research and reviews 20080101

Evaluation of gliclazide ability to attenuate the hyperglycaemic 'memory' induced by high glucose in isolated human endothelial cells.

Diabetes/metabolism research and reviews 20080101

Development of extended zero-order release gliclazide tablets by central composite design.

Drug development and industrial pharmacy 20080101

Probiotic treatment reduces blood glucose levels and increases systemic absorption of gliclazide in diabetic rats.

European journal of drug metabolism and pharmacokinetics 20080101

Influence of the semisynthetic bile acid (MKC) on the ileal permeation of gliclazide in healthy and diabetic rats.

Pharmacological reports : PR 20080101

Vascular and renal benefits are additive using intensive blood pressure control and incremental glucose control in type 2 diabetic patients.

Cardiovascular journal of Africa 20080101

The influence of 3alpha,7alpha-dihydroxy-12-keto-5beta-cholanate on gliclazide pharmacokinetics and glucose levels in a rat model of diabetes.

European journal of drug metabolism and pharmacokinetics 20080101

Liquid chromatography--mass spectrometry method for the determination of gliclazide in human plasma and application to a pharmacokinetic study of gliclazide sustained release tablets.

Arzneimittel-Forschung 20080101

Gliclazide inhibits proliferation but stimulates differentiation of white and brown adipocytes.

Journal of biochemistry 20071101

Identification of the human cytochromes P450 catalysing the rate-limiting pathways of gliclazide elimination.

British journal of clinical pharmacology 20071001

The influence of hydro-alcoholic media on hypromellose matrix systems.

Drug development and industrial pharmacy 20071001

[Advanced credit: patient enrolling and therapy initiation in the ADVANCE trial].

Orvosi hetilap 20070930

Are sulphonylureas all the same? A cohort study on cardiovascular and cancer-related mortality.

Diabetes/metabolism research and reviews 20070901

'Warm-up' phenomenon in diabetic patients with stable angina treated with diet or sulfonylureas.

Coronary artery disease 20070901

Long-term effects of pioglitazone versus gliclazide on hepatic and humoral coagulation factors in patients with type 2 diabetes.

Diabetes & vascular disease research 20070901

Effects of glibenclamide, glimepiride, and gliclazide on ischemic preconditioning in rat heart.

Chinese medical sciences journal = Chung-kuo i hsueh k'o hsueh tsa chih 20070901

Controlling of systemic absorption of gliclazide through incorporation into alginate beads.

International journal of pharmaceutics 20070816

Comparisons between the beneficial effects of different sulphonylurea treatments on ischemia-induced retinal neovascularization.

Free radical biology & medicine 20070801

Association of sulfonylurea receptor 1 genotype with therapeutic response to gliclazide in type 2 diabetes.

Diabetes research and clinical practice 20070701

Influence of CYP2C9 and CYP2C19 genetic polymorphisms on pharmacokinetics of gliclazide MR in Chinese subjects.

British journal of clinical pharmacology 20070701

Gliclazide: pharmacokinetic-pharmacodynamic relationships in rats.

Biopharmaceutics & drug disposition 20070701

Nateglinide or gliclazide in combination with metformin for treatment of patients with type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone: 1-year trial results.

Diabetes, obesity & metabolism 20070701

In-vitro and in-vivo correlation for two gliclazide extended-release tablets.

The Journal of pharmacy and pharmacology 20070701

Development of a RP-HPLC method for screening potentially counterfeit anti-diabetic drugs.

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20070615

New insights from ADVANCE.

Journal of hypertension. Supplement : official journal of the International Society of Hypertension 20070601

Insulinoma causing hypoglycemia in a patient with type 2 diabetes.

Journal of the Formosan Medical Association = Taiwan yi zhi 20070501

Mixture modeling for the detection of subpopulations in a pharmacokinetic/pharmacodynamic analysis.

Journal of pharmacokinetics and pharmacodynamics 20070401

Gliclazide protects human islet beta-cells from apoptosis induced by intermittent high glucose.

Diabetes/metabolism research and reviews 20070301

A bioequivalence study of gliclazide based on quantification by high-performance liquid chromatography coupled with electrospray tandem mass spectrometry.

International journal of clinical pharmacology and therapeutics 20070301

Comparison of the solubility and dissolution rate between gliclazide solid complex and its nanospheres.

Drug development and industrial pharmacy 20070301

Dual aetiologies for hyperinsulinaemic hypoglycaemia in one patient.

Hong Kong medical journal = Xianggang yi xue za zhi 20070201

Preparation and in vitro/in vivo evaluation of gliclazide loaded Eudragit nanoparticles as a sustained release carriers.

Drug development and industrial pharmacy 20070201

Beneficial effects of gliclazide modified release compared with glibenclamide on endothelial activation and low-grade inflammation in patients with type 2 diabetes.

Diabetes, obesity & metabolism 20070101

The mushroom Agaricus Blazei Murill in combination with metformin and gliclazide improves insulin resistance in type 2 diabetes: a randomized, double-blinded, and placebo-controlled clinical trial.

Journal of alternative and complementary medicine (New York, N.Y.) 20070101

Impact of the short-term, intense exercise on postprandial glycemia in type 2 diabetic patients treated with gliclazide.

Journal of diabetes and its complications 20070101

In vivo and in vitro evaluation of a solid dispersion system of gliclazide:PEG 6000.

PDA journal of pharmaceutical science and technology 20070101

A case of mistaken identity.

Hong Kong medical journal = Xianggang yi xue za zhi 20061201

Effect of Kaiyu Qingwei Jianji on the morphometry and residual strain distribution of small intestine in experimental diabetic rats.

World journal of gastroenterology 20061128

Association of gliclazide and left ventricular mass in type 2 diabetic patients.

Diabetes research and clinical practice 20061101

Actions of ZD0947, a novel ATP-sensitive K+ channel opener, on membrane currents in human detrusor myocytes.

British journal of pharmacology 20061101

Activation of nicotinamide adenine dinucleotide phosphate (reduced form) oxidase by advanced glycation end products links oxidative stress to altered retinal vascular endothelial growth factor expression.

Metabolism: clinical and experimental 20061101

Effects of isopropyl palmitate on the skin permeation of drugs.

Biological & pharmaceutical bulletin 20061101

Application of monolithic column in quantification of gliclazide in human plasma by liquid chromatography.

Journal of pharmaceutical and biomedical analysis 20061011

Simultaneous estimation of six anti-diabetic drugs--glibenclamide, gliclazide, glipizide, pioglitazone, repaglinide and rosiglitazone: development of a novel HPLC method for use in the analysis of pharmaceutical formulations and its application to human plasma assay.

Biomedical chromatography : BMC 20061001

Influence of nicorandil on the pharmacodynamics and pharmacokinetics of gliclazide in rats and rabbits.

Molecular and cellular biochemistry 20061001

Effect of gliclazide modified release on adiponectin, interleukin-6, and tumor necrosis factor-alpha plasma levels in individuals with type 2 diabetes mellitus.

Current medical research and opinion 20061001

Effect of gliclazide on DNA damage in human peripheral blood lymphocytes and insulinoma mouse cells.

Chemico-biological interactions 20060925

Metrics for external model evaluation with an application to the population pharmacokinetics of gliclazide.

Pharmaceutical research 20060901

Gliclazide treatment lowers serum ICAM-1 levels in poorly controlled type 2 diabetic patients.

Diabetes & metabolism 20060901

Clinical observation on effect of Kaixin capsule in treating 40 patients with diabetic myocardial ischemia.

Chinese journal of integrative medicine 20060901

ADVANCE: breaking new ground in type 2 diabetes.

Journal of hypertension. Supplement : official journal of the International Society of Hypertension 20060801

Antidiabetic activity of an ethanol extract obtained from the stem bark of Psidium guajava (Myrtaceae).

Die Pharmazie 20060801

[Rhabdomyolysis induced by fenofibrate monotherapy].

La Revue de medecine interne 20060701

Is it time to re-assess the role of gliclazide? Targeting insulin resistance in type 2 diabetes patients suboptimally controlled with insulin.

Postgraduate medical journal 20060701

Comparison of nateglinide and gliclazide in combination with metformin, for treatment of patients with Type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone.

Diabetic medicine : a journal of the British Diabetic Association 20060701

A mechanism-based disease progression model for comparison of long-term effects of pioglitazone, metformin and gliclazide on disease processes underlying Type 2 Diabetes Mellitus.

Journal of pharmacokinetics and pharmacodynamics 20060601

Gliclazide protects 3T3L1 adipocytes against insulin resistance induced by hydrogen peroxide with restoration of GLUT4 translocation.

Metabolism: clinical and experimental 20060601

Gliclazide inhibits differentiation-associated biologic events in human monocyte-derived macrophages.

Metabolism: clinical and experimental 20060601

Effects of gliclazide beyond metabolic control.

Metabolism: clinical and experimental 20060501

Lymphocyte ecto-5'-nucleotidase in obese type 2 diabetic patients treated with gliclazide.

Diabetes & metabolism 20060401

Double-blind, randomized, multicentre study of the efficacy and safety of gliclazide-modified release in the treatment of Chinese type 2 diabetic patients.

Diabetes, obesity & metabolism 20060301

Comparison of glycaemic control over 1 year with pioglitazone or gliclazide in patients with Type 2 diabetes.

Diabetic medicine : a journal of the British Diabetic Association 20060301

Anti-diabetic and hypolipidemic effects of aqueous-extract from the flower of Inula japonica in alloxan-induced diabetic mice.

Biological & pharmaceutical bulletin 20060301

Influence of selenium (antioxidant) on gliclazide induced hypoglycaemia/anti hyperglycaemia in normal/alloxan-induced diabetic rats.

Molecular and cellular biochemistry 20060201

Comparison of the antioxidant and vascular effects of gliclazide and glibenclamide in Type 2 diabetic patients: a randomized crossover study.

Journal of diabetes and its complications 20060101

Three-year mortality in diabetic patients treated with different combinations of insulin secretagogues and metformin.

Diabetes/metabolism research and reviews 20060101

Development and validation of a new high-performance liquid chromatography method for the determination of gliclazide and repaglinide in pharmaceutical formulations.

Journal of AOAC International 20060101

Single and multiple dose bioequivalence evaluation of two brands of gliclazide modified release tablets in healthy Chinese male volunteers.

Arzneimittel-Forschung 20060101

The effectiveness of various doses of octreotide for sulfonylurea-induced hypoglycemia after overdose.

Advances in therapy 20060101

Secondary sulfonylurea failure: comparison of period until insulin treatment between diabetic patients treated with gliclazide and glibenclamide.

Diabetes research and clinical practice 20051201

Activation of KATP channels by H2S in rat insulin-secreting cells and the underlying mechanisms.

The Journal of physiology 20051201

Long-term effects on lipids and lipoproteins of pioglitazone versus gliclazide addition to metformin and pioglitazone versus metformin addition to sulphonylurea in the treatment of type 2 diabetes.

Diabetologia 20051201

The DIACOM study (effect of DosIng frequency of oral Antidiabetic agents on the COMpliance and biochemical control of type 2 diabetes).

Diabetes, obesity & metabolism 20051101

Simultaneous determination of metformin and gliclazide in human plasma by liquid chromatography-tandem mass spectrometry: application to a bioequivalence study of two formulations in healthy volunteers.

Journal of mass spectrometry : JMS 20051101

[The multi-level Meta analysis model combining individual level data with aggregative level data].

Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition 20051101

Safety and tolerability of pioglitazone, metformin, and gliclazide in the treatment of type 2 diabetes.

Diabetes research and clinical practice 20051001

Synthesis and characterization of gliclazide complexes of magnesium, calcium, chromium, manganese, iron, nickel, copper, zinc and cadmium salts.

Pakistan journal of pharmaceutical sciences 20051001

[A multicenter clinic study of slow-release-gliclazide in type 2 diabetes mellitus].

Zhonghua yi xue za zhi 20050928

High-performance liquid chromatography with electrochemical detection for analysis of gliclazide in plasma.

Journal of chromatography. A 20050923

Determination of aminoheterocycle and azabicycle in gliclazide bulk by capillary zone electrophoresis with amperometric detection.

Journal of pharmaceutical and biomedical analysis 20050915

Management of diabetes during Ramadan.

Diabetic medicine : a journal of the British Diabetic Association 20050901

Gliclazide attenuates the intracellular Ca2+ changes induced in vitro by ischemia in the retinal slices of rats with streptozotocin-induced diabetes.

Current eye research 20050901

Changes in liver tests during 1-year treatment of patients with Type 2 diabetes with pioglitazone, metformin or gliclazide.

Diabetic medicine : a journal of the British Diabetic Association 20050801

Confusing tablets.

Lancet (London, England) 20050701

Long-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes.

Diabetologia 20050601

Pharmaceutical availability of gliclazide from selected matrix formulation tablets.

Medical science monitor : international medical journal of experimental and clinical research 20050601

Efficacy of glimepiride in Japanese type 2 diabetic subjects.

Diabetes research and clinical practice 20050601

The effect of gliclazide and glibenclamide on preconditioning of the human myocardium.

European journal of pharmacology 20050516

[Controversial therapeutic strategies in the treatment of type 2 diabetes mellitus].

MMW Fortschritte der Medizin 20050428

A long-term comparison of pioglitazone and gliclazide in patients with Type 2 diabetes mellitus: a randomized, double-blind, parallel-group comparison trial.

Diabetic medicine : a journal of the British Diabetic Association 20050401

The development and validation of liquid chromatography method for the simultaneous determination of metformin and glipizide, gliclazide, glibenclamide or glimperide in plasma.

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20050325

[54-year-old patient with type 2 diabetes mellitus and increased blood pressure values].

Praxis 20050316

Comparison of pioglitazone and gliclazide in sustaining glycemic control over 2 years in patients with type 2 diabetes.

Diabetes care 20050301

Pioglitazone elicits long-term improvements in insulin sensitivity in patients with type 2 diabetes: comparisons with gliclazide-based regimens.

Diabetologia 20050301

The effect of short-term glycemic regulation with gliclazide and metformin on postprandial lipemia.

Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association 20050201

Long-term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: a randomized, comparative study.

Diabetes/metabolism research and reviews 20050101

Effect of repaglinide and gliclazide on postprandial control of endogenous glucose production.

Metabolism: clinical and experimental 20050101

Forearm vascular reactivity is differentially influenced by gliclazide and glibenclamide in chronically treated type 2 diabetic patients.

Clinical physiology and functional imaging 20050101

Gliclazide modified release.

Drugs 20050101

Effect of I-deprenyl and gliclazide on oxidant stress/antioxidant status and dna damage in a diabetic rat model.

Endocrine research 20050101

Effect of aqueous extract of Cyamopsis tetragonoloba Linn. beans on blood glucose level in normal and alloxan-induced diabetic rats.

Indian journal of experimental biology 20041201

Gliclazide modified release: results of a 2-year study in patients with type 2 diabetes.

Diabetes, obesity & metabolism 20041101

Metformin or gliclazide, rather than glibenclamide, attenuate progression of carotid intima-media thickness in subjects with type 2 diabetes.

Diabetologia 20041101

Effects of pioglitazone on the components of diabetic dyslipidaemia: results of double-blind, multicentre, randomised studies.

International journal of clinical practice 20041001

[Therapy objectives and daily practice--to which extent are blood sugar target values accessible in daily practice?].

Praxis 20040929

Taurine block of cloned ATP-sensitive K+ channels with different sulfonylurea receptor subunits expressed in Xenopus laevis oocytes.

Biochemical pharmacology 20040901

Cardiovascular effects of treatment of type 2 diabetes with pioglitazone, metformin and gliclazide.

International journal of clinical practice 20040901

Studies on the glycemic and lipidemic effect of monopril and losartan in normal and diabetic rats.

Pharmacological research 20040801

GUIDE study: double-blind comparison of once-daily gliclazide MR and glimepiride in type 2 diabetic patients.

European journal of clinical investigation 20040801

Efficacy and safety of once daily gliclazide (20 mg/day) compared with nateglinide.

Endocrine journal 20040801

[2-year data of large clinical comparative studies. Type 2 diabetes: lasting metabolic control with pioglitazone].

MMW Fortschritte der Medizin 20040722

[The efficacy and safety of 30 mg slow-released-gliclazide in type 2 diabetes mellitus].

Zhonghua nei ke za zhi 20040701

Quantification of gliclazide by semi-micro high-performance liquid chromatography: application to a bioequivalence study of two formulations in healthy subjects.

Journal of pharmaceutical and biomedical analysis 20040629

Advanced glycation end-products increase monocyte adhesion to retinal endothelial cells through vascular endothelial growth factor-induced ICAM-1 expression: inhibitory effect of antioxidants.

Journal of leukocyte biology 20040601

Metformin attenuates progression of carotid arterial wall thickness in patients with type 2 diabetes.

Diabetes research and clinical practice 20040601

Normal pregnancy outcome following inadvertent exposure to rosiglitazone, gliclazide, and atorvastatin in a diabetic and hypertensive woman.

Reproductive toxicology (Elmsford, N.Y.) 20040601

Comparison of uptitration of gliclazide with the addition of rosiglitazone to gliclazide in patients with type 2 diabetes inadequately controlled on half-maximal doses of a sulphonylurea.

Acta diabetologica 20040601

Octreotide treatment for sulfonylurea-induced hypoglycaemia.

The Medical journal of Australia 20040517

Gliclazide at a lower concentration than therapeutic dose increases the sensitivity of insulin secretion to glucose in perfused rat pancreas.

Diabetes & metabolism 20040401

[Long-term HbA1c stable. Insulin sensitizer keeps diabetes in check].

MMW Fortschritte der Medizin 20040325

Erosion induced controllable release of gliclazide encapsulated inside degradable polymeric particles.

Macromolecular bioscience 20040315

Signalling pathways involved in retinal endothelial cell proliferation induced by advanced glycation end products: inhibitory effect of gliclazide.

Diabetes, obesity & metabolism 20040301

NMDA receptor subunits 2A and 2B decrease and lipid peroxidation increase in the hippocampus of streptozotocin-diabetic rats: effects of insulin and gliclazide treatments.

The International journal of neuroscience 20040301

Radical scavenging effect of gliclazide in diabetic rats fed with a high cholesterol diet.

Kidney international 20040301

Effect of antidiabetic medications on microalbuminuria in patients with type 2 diabetes.

Metabolism: clinical and experimental 20040301

Myocardial protection from either ischaemic preconditioning or nicorandil is not blocked by gliclazide.

Cardiovascular drugs and therapy 20040301

[Compliance and optimisation of oral antidiabetic therapy. A longitudinal study].

Presse medicale (Paris, France : 1983) 20040214

Phosphatidylinositol 3-kinase activation is required for sulfonylurea stimulation of glucose transport in rat skeletal muscle.

Endocrinology 20040201

Long-term glycaemic control with pioglitazone in patients with type 2 diabetes.

International journal of clinical practice 20040201

Favorable effects of pioglitazone and metformin compared with gliclazide on lipoprotein subfractions in overweight patients with early type 2 diabetes.

Diabetes care 20040101

Protective actions of gliclazide on high insulin-enhanced neutrophil-endothelial cell interactions through inhibition of mitogen activated protein kinase and protein kinase C pathways.

Microvascular research 20040101

Spectrophotometric determination of gliclazide in pharmaceuticals and biological fluids through ternary complex formation with eosin and palladium (II).

Farmaco (Societa chimica italiana : 1989) 20040101

The antidiabetic agent, gliclazide, reduces high insulin-enhanced neutrophil-transendothelial migration through direct effects on the endothelium.

Diabetes/metabolism research and reviews 20040101

NIDDM: new once-daily intervention for type 2 diabetes mellitus: Diaprel MR.

Romanian journal of internal medicine = Revue roumaine de medecine interne 20040101

[A prospective randomized study of sulphonylureas therapeutic interchange in patients with type 2 diabetes mellitus].

Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria 20040101

Comparison of repaglinide vs. gliclazide in combination with bedtime NPH insulin in patients with Type 2 diabetes inadequately controlled with oral hypoglycaemic agents.

Diabetic medicine : a journal of the British Diabetic Association 20031101

Genetic cause of hyperglycaemia and response to treatment in diabetes.

Lancet (London, England) 20031018

Effect of rifampin on the pharmacokinetics and pharmacodynamics of gliclazide.

Clinical pharmacology and therapeutics 20031001

Monotherapy of type 2 diabetes with once-daily gliclazide modified release in primary care.

Diabetes research and clinical practice 20031001

[Medication of the month. Gliclazide modified release (Uni Diamicron)].

Revue medicale de Liege 20031001

Reflex epilepsy and non-ketotic hyperglycemia.

Epileptic disorders : international epilepsy journal with videotape 20030901

Benefits of gliclazide in the atherosclerotic process: decrease in monocyte adhesion to endothelial cells.

Metabolism: clinical and experimental 20030801

Gliclazide modified release: A critical review of pharmacodynamic, metabolic, and vasoprotective effects.

Metabolism: clinical and experimental 20030801

Bioequivalence study of generic gliclazide and Diamicron formulations in healthy Thai male volunteers.

International journal of clinical pharmacology and therapeutics 20030701

The application of the convective diffusion model and the film equilibrium model to surfactant-facilitated dissolution of gliclazide.

European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 20030701

Pharmacokinetic and pharmacodynamic characterization of gliclazide in healthy volunteers.

Archives of pharmacal research 20030701

Functional involvement of sulphonylurea receptor (SUR) type 1 and 2B in the activity of pig urethral ATP-sensitive K+ channels.

British journal of pharmacology 20030601

Comparison of the micro- and macro-vascular effects of glimepiride and gliclazide in metformin-treated patients with Type 2 diabetes: a double-blind, crossover study.

British journal of clinical pharmacology 20030601

Diabetes and vascular disease: a new international trial.

Asian cardiovascular & thoracic annals 20030601

Urinary PC-1 and N-acetyl-beta-D-glucosaminidase activity in patients with type 2 diabetes treated with metformin, gliclazide or glibenclamide.

Annals of clinical biochemistry 20030501

Study of the solubilization of gliclazide by aqueous micellar solutions.

Journal of pharmaceutical sciences 20030401

Gliclazide protects pancreatic beta-cells from damage by hydrogen peroxide.

Biochemical and biophysical research communications 20030328

A simple and sensitive HPLC method for determination of gliclazide in human serum.

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20030305

Population PKPD modelling of the long-term hypoglycaemic effect of gliclazide given as a once-a-day modified release (MR) formulation.

British journal of clinical pharmacology 20030201

Differential effects of sulphonylureas on the vasodilatory response evoked by K(ATP) channel openers.

Fundamental & clinical pharmacology 20030201

Diabetes mellitus and weight control: differences of respiratory quotient in type 2 diabetic obese subjects receiving sulfonylureas and non-diabetic obese controls.

Nutrition (Burbank, Los Angeles County, Calif.) 20030201

Severe relapsing sulphonylurea-induced hypoglycaemia: a diagnostic and therapeutic challenge.

Postgraduate medical journal 20030201

The mechanisms of inhibitory actions of gliclazide on neutrophils-endothelial cells adhesion and surface expression of endothelial adhesion molecules mediated by a high glucose concentration.

Journal of diabetes and its complications 20030101

Effects of inhibition of ATP-sensitive potassium channels on metabolic vasodilation in the human forearm.

Clinical science (London, England : 1979) 20030101

Effects of sulfonylureas on K(ATP) channel-dependent vasodilation.

Journal of diabetes and its complications 20030101

Monocyte adhesion in diabetic angiopathy: effects of free-radical scavenging.

Journal of diabetes and its complications 20030101

Diabetic endothelial dysfunction: effect of free radical scavenging in Type 2 diabetic patients.

Journal of diabetes and its complications 20030101

Spectrofluorimetric and spectrophotometric determination of gliclazide in pharmaceuticals by derivatization with 4-chloro-7-nitrobenzo-2-oxa-1,3-diazole.

Journal of AOAC International 20030101

Addition of rosiglitazone to existing sulfonylurea treatment in chinese patients with type 2 diabetes and exposure to hepatitis B or C.

Diabetes technology & therapeutics 20030101

Gliclazide increases insulin receptor tyrosine phosphorylation but not p38 phosphorylation in insulin-resistant skeletal muscle cells.

The Journal of experimental biology 20021201

Interaction of the cytosolic domains of the Kir6.2 subunit of the K(ATP) channel is modulated by sulfonylureas.

Diabetes 20021201

Gliclazide directly inhibits arginine-induced glucagon release.

Diabetes 20021201

Combination therapy of alpha-glucosidase inhibitor and a sulfonylurea compound prolongs the duration of good glycemic control.

Metabolism: clinical and experimental 20021201

Hypoglycaemic activity of Alpinia galanga rhizome and its extracts in rabbits.

Fitoterapia 20021201

Eudragit NE30D based metformin/gliclazide extended release tablets: formulation, characterisation and in vitro release studies.

Chemical & pharmaceutical bulletin 20021101

Effect of gliclazide on islet transplants.

Transplantation proceedings 20021101

Remodelling of zero-stress state of small intestine in streptozotocin-induced diabetic rats. Effect of gliclazide.

Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 20021001

Gliclazide improves anti-oxidant status and nitric oxide-mediated vasodilation in Type 2 diabetes.

Diabetic medicine : a journal of the British Diabetic Association 20020901

A novel simple method for the investigation of drug binding to the K(ATP) channel sulfonylurea receptor.

Analytical biochemistry 20020815

Bioequivalence evaluation of two brands of gliclazide 80 mg tablets (Glyzide & Diamicron)--in healthy human volunteers.

Biopharmaceutics & drug disposition 20020701

Oral hypoglycaemic agent failure.

Journal of the Indian Medical Association 20020701

Acute gliclazide administration enhances glucose and ketone body utilization in the perfused hind limb of normal and streptozotocin-diabetic rats.

Life sciences 20020628

Effect of pioglitazone on blood proinsulin levels in patients with type 2 diabetes mellitus.

Endocrine journal 20020601

Complete bioavailability and lack of food-effect on pharmacokinetics of gliclazide 30 mg modified release in healthy volunteers.

Biopharmaceutics & drug disposition 20020501

Gliclazide-induced acute hepatitis with hypersensitivity features.

Digestive diseases and sciences 20020501

Effective and selective prevention of retinal leukostasis in streptozotocin-induced diabetic rats using gliclazide.

Diabetologia 20020501

Studies on solubility and hypoglycemic activity of gliclazide beta-cyclodextrin-hydroxypropylmethylcellulose complexes.

Die Pharmazie 20020301

Does gliclazide stimulate first-phase, second-phase, or both phases of insulin release?

Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme 20020201

Gliclazide modified release.

Drugs 20020101

Advanced glycation end products increase, through a protein kinase C-dependent pathway, vascular endothelial growth factor expression in retinal endothelial cells. Inhibitory effect of gliclazide.

Journal of diabetes and its complications 20020101

Effect of ethanolic extract of Embelia ribes on dyslipidemia in diabetic rats.

International journal of experimental diabetes research 20020101

Regulation of glucose transporter 1 expression by gliclazide in rat L6 myoblasts.

Diabetes, nutrition & metabolism 20011201

Increments in insulin sensitivity during intensive treatment are closely correlated with decrements in glucocorticoid receptor mRNA in skeletal muscle from patients with Type II diabetes.

Clinical science (London, England : 1979) 20011101

Possible interaction between gliclazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia.

British journal of clinical pharmacology 20011001

Study rationale and design of ADVANCE: action in diabetes and vascular disease--preterax and diamicron MR controlled evaluation.

Diabetologia 20010901

Acute and short-term administration of a sulfonylurea (gliclazide) increases pulsatile insulin secretion in type 2 diabetes.

Diabetes 20010801

Gliclazide produces high-affinity block of KATP channels in mouse isolated pancreatic beta cells but not rat heart or arterial smooth muscle cells.

Diabetologia 20010801

Glibenclamide vs gliclazide in reducing oxidative stress in patients of noninsulin dependent diabetes mellitus--a double blind randomized study.

The Journal of the Association of Physicians of India 20010801

Gliclazide decreases vascular smooth muscle cell dysfunction induced by cell-mediated oxidized low-density lipoprotein.

Metabolism: clinical and experimental 20010601

Gliclazide mainly affects insulin secretion in second phase of type 2 diabetes mellitus.

Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme 20010601

ATP-Sensitive potassium channels modulate glucose transport in cultured human skeletal muscle cells.

Endocrine journal 20010601

[Effects of gliclazide on blood rheology of diabetes Wistar rat].

Hua xi yi ke da xue xue bao = Journal of West China University of Medical Sciences = Huaxi yike daxue xuebao 20010601

Characteristics of pancreatic beta-cell secretion in Type 2 diabetic patients treated with gliclazide and glibenclamide.

Diabetes research and clinical practice 20010501

ION-pair liquid chromatography technique for the estimation of metformin in its multicomponent dosage forms.

Journal of pharmaceutical and biomedical analysis 20010401

Sulfonylurea treatment of type 2 diabetic patients does not reduce the vasodilator response to ischemia.

Diabetes care 20010401

24-hour glycemic profile in type 2 diabetic patients treated with gliclazide modified release once daily.

Diabetes & metabolism 20010401

Effect of KAD-1229, a nonsulfonylurea hypoglycemic agent, on plasma glucose and insulin in streptozotocin-induced diabetic dogs.

Pharmacology 20010201

Gliclazide and bedtime insulin are more efficient than insulin alone for type 2 diabetic patients with sulfonylurea secondary failure.

Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas 20010101

Comparison of acarbose and gliclazide as first-line agents in patients with type 2 diabetes.

Current medical research and opinion 20010101

[Free radical scavenging activity of sulfonylureas: a clinical assessment of the effectiveness of gliclazide].

Terapevticheskii arkhiv 20010101

Gliclazide-induced hepatitis, hemiplegia and dysphasia in a suicide attempt.

Journal of pediatric endocrinology & metabolism : JPEM 20010101

[Toxicological analysis in the dawn of the third millenium].

Annales de biologie clinique 20010101

[Recurrent toxic severe hypoglycemias].

Annales de biologie clinique 20010101

Determination of gliclazide in pharmaceutical preparations by capillary gas chromatography with cool on-column injection and elimination of the matrix effect.

Journal of AOAC International 20010101

[Antioxidant and anti-AGE therapeutics: evaluation and perspectives].

Journal de la Societe de biologie 20010101

Gliclazide-induced acute hepatitis.

European journal of gastroenterology & hepatology 20000101

Cardiovascular effects of conventional sulfonylureas and glimepiride.

Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme 19960901

Possible gliclazide-induced water retention with azotemia.

Internal medicine (Tokyo, Japan) 19940301